Renovaro Biosciences Stock Today
| RENB Stock | 1.49 0.01 0.68% |
Performance0 of 100
| Odds Of DistressLess than 23
|
Renovaro Biosciences is trading at 1.49 as of the 8th of May 2024, a 0.68 percent increase since the beginning of the trading day. The stock's open price was 1.48. Renovaro Biosciences has about a 23 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Renovaro Biosciences symbol was changed from ENOB on 7th of August 2023. Equity ratings for Renovaro Biosciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 19th of May 2022 and ending today, the 8th of May 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of February 2015 | Category Healthcare | Classification Health Care |
Renovaro Biosciences is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 143.67 M outstanding shares of which 2.2 M shares are at this time shorted by private and institutional investors with about 6.5 trading days to cover. More on Renovaro Biosciences
Moving against Renovaro Stock
| 0.56 | ELYM | Eliem Therapeutics Trending | PairCorr |
| 0.41 | MRK | Merck Company Financial Report 6th of August 2024 | PairCorr |
Renovaro Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Renovaro Biosciences' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Renovaro Biosciences or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Older Symbol | ENOB | |||||||||||||||||||||||||||||||||||||||||||||
| Director CEO | Mark MD | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Renovaro Biosciences' liquidity, profitability, solvency, and operating efficiency, Renovaro Biosciences is not in a good financial situation at this time. It has a very high odds of going through financial crisis in June. Financial strength of Renovaro Biosciences is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||
Renovaro Biosciences' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Renovaro Biosciences' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Renovaro Biosciences' financial leverage. It provides some insight into what part of Renovaro Biosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Renovaro Biosciences (RENB) is traded on NASDAQ Exchange in USA. It is located in 2080 Century Park East, Los Angeles, CA, United States, 90067 and employs 12 people. Renovaro Biosciences was previously known as ENOB Old and was traded on NASDAQ Exchange under the symbol ENOB. Renovaro Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 214.07 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Renovaro Biosciences's market, we take the total number of its shares issued and multiply it by Renovaro Biosciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Renovaro Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 143.67 M outstanding shares of which 2.2 M shares are at this time shorted by private and institutional investors with about 6.5 trading days to cover.
Renovaro Biosciences generates negative cash flow from operations
Check Renovaro Biosciences Probability Of Bankruptcy
Ownership AllocationRenovaro Biosciences has a total of 143.67 Million outstanding shares. Renovaro Biosciences has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Renovaro Ownership Details
Renovaro Stock Price Odds Analysis
What are Renovaro Biosciences' target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Renovaro Biosciences jumping above the current price in 90 days from now is under 95%. The Renovaro Biosciences probability density function shows the probability of Renovaro Biosciences stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.682 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Renovaro Biosciences will likely underperform. Additionally, renovaro Biosciences has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Renovaro Biosciences to move above the current price in 90 days from now is under 95 (This Renovaro Biosciences probability density function shows the probability of Renovaro Stock to fall within a particular range of prices over 90 days) .
Renovaro Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Renovaro Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Renovaro Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Renovaro Biosciences' value.| Instituion | Recorded On | Shares | |
| Citigroup Inc | 2023-12-31 | 50.9 K | |
| Bank Of America Corp | 2023-12-31 | 46.3 K | |
| Dimensional Fund Advisors, Inc. | 2023-12-31 | 36.1 K | |
| Jpmorgan Chase & Co | 2023-12-31 | 29.8 K | |
| Balyasny Asset Management Llc | 2023-12-31 | 25.8 K | |
| Goldman Sachs Group Inc | 2023-12-31 | 25.7 K | |
| Msa Advisors Llc | 2023-12-31 | 25 K | |
| Exoduspoint Capital Management, Lp | 2023-12-31 | 25 K | |
| Boothbay Fund Management, Llc | 2023-12-31 | 20.4 K | |
| Vanguard Group Inc | 2023-12-31 | 390.1 K | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 363 K |
Renovaro Biosciences Historical Income Statement
Renovaro Biosciences Income Statement is one of the three primary financial statements used for reporting Renovaro's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Renovaro Biosciences revenue and expense. Renovaro Biosciences Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Renovaro Biosciences' Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 17.3 M, whereas Operating Income is projected to grow to (99.2 M). View More FundamentalsRenovaro Stock Against Markets
Picking the right benchmark for Renovaro Biosciences stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Renovaro Biosciences stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Renovaro Biosciences is critical whether you are bullish or bearish towards Renovaro Biosciences at a given time. Please also check how Renovaro Biosciences' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Renovaro Biosciences without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Equity Search Now
Equity SearchSearch for actively traded equities including funds and ETFs from over 30 global markets |
| All Next | Launch Module |
Renovaro Biosciences Corporate Management
Elected by the shareholders, the Renovaro Biosciences' board of directors comprises two types of representatives: Renovaro Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Renovaro. The board's role is to monitor Renovaro Biosciences' management team and ensure that shareholders' interests are well served. Renovaro Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Renovaro Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Greg Duczynski | Senior Operations | Profile | |
| Simon Tarsh | Interim Officer | Profile | |
| Evelyn DAn | Consultant | Profile | |
| Franois MSc | Ex RD | Profile |
How to buy Renovaro Stock?
Before investing in Renovaro Biosciences, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Renovaro Biosciences. To buy Renovaro Biosciences stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Renovaro Biosciences. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Renovaro Biosciences stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Renovaro Biosciences stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Renovaro Biosciences stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Renovaro Biosciences, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Renovaro Stock please use our How to Invest in Renovaro Biosciences guide.
Already Invested in Renovaro Biosciences?
The danger of trading Renovaro Biosciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Renovaro Biosciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Renovaro Biosciences. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Renovaro Biosciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Renovaro Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Renovaro Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Renovaro Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Renovaro Biosciences Stock: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Renovaro Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Renovaro Stock refer to our How to Trade Renovaro Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for Renovaro Stock analysis
When running Renovaro Biosciences' price analysis, check to measure Renovaro Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Renovaro Biosciences is operating at the current time. Most of Renovaro Biosciences' value examination focuses on studying past and present price action to predict the probability of Renovaro Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Renovaro Biosciences' price. Additionally, you may evaluate how the addition of Renovaro Biosciences to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is Renovaro Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Renovaro Biosciences. If investors know Renovaro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Renovaro Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.70) | Return On Assets (0.19) | Return On Equity (0.75) |
The market value of Renovaro Biosciences is measured differently than its book value, which is the value of Renovaro that is recorded on the company's balance sheet. Investors also form their own opinion of Renovaro Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Renovaro Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Renovaro Biosciences' market value can be influenced by many factors that don't directly affect Renovaro Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Renovaro Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Renovaro Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Renovaro Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.